Cell Host Microbe 2, 316–327 (2007). Article CAS PubMed PubMed Central Google Scholar Ancsin, J.B. & Kisilevsky, R. A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoite protein: significance for malarial sporozoite attachment to ...
The use of monoclonal antibodies for the control of drug resistant nosocomial bacteria may alleviate a reliance on broad spectrum antimicrobials for treatment of infection. We identify monoclonal antibodies that may prevent infection caused by carbapenem resistantAcinetobacter baumannii. We use human immune ...
Cell Host Microbe https://doi.org/10.1016/j.chom.2020.06.021 (2020). Rogers, T. F. et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. Science https://doi.org/10.1126/science.abc7520 (2020). Robbiani, D. F. et al. Convergent...
Cell Host Microbe 29, 477–488 (2021). Article CAS PubMed PubMed Central Google Scholar Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717–726 (2021). Article CAS PubMed PubMed Central ...
The SARS-CoV-2 nucleocapsid protein (NP) is an important indicator for the virus infection, highlighting the crucial role of NP-specific monoclonal antibodies (mAbs) used in multiple biochemical assays and clinical diagnosis for detecting the NP antigen. Here, we reported a pair of noncompeting ...
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29, 529–539 (2021). e3. Article CAS Google Scholar Yadav, P. D. et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. Clin....
Human immunodeficiency virus (HIV)-1-specific broadly neutralizing monoclonal antibodies are currently under development to treat and prevent HIV-1 infection. We performed a single-center, randomized, double-blind, dose-escalation, placebo-controlled tri
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel coronavirus disease (COVID-19). The neutralizing monoclonal antibodies (mAbs) targeting the receptor-binding domain (RBD) of SARS-CoV-2 are among the m
Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system Philipp A. Ilinykh Kai Huang Alexander Bukreyev Communications Biology(2024) Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility ...
The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria